Park Medi World Ltd Q1 FY2027 Concall Summary

Key Takeaways

• 19% revenue growth, margin expansion: Revenue grew 19% YoY while PAT margin expanded 220 bps, driven by a case-mix shift toward high-end tertiary and quaternary care and a sharp reduction in interest costs after substantial debt repayment.
• Occupancy dipped to 56% as 960 beds came online: Network occupancy fell from 68% to 56% because beds added at Bhatinda, Agra, and Panchkula entered the denominator immediately while still ramping up, a mechanical drag management flagged as temporary.
• Three acquisitions announced, one already commissioned: Rudrapur (330 beds, commissioned 2 Aug), Zirakpur (150 beds, ~₹107 cr), and a 100-bed Palam Vihar extension were all announced, pushing the identified bed pipeline to 5,740 by FY28, fully funded without fresh debt.
• CGHS rate revision benefit partly reinvested: A 7–7.5% CGHS rate hike began flowing in Q1, with fuller impact from Q2, but management expects the benefit to be ploughed into equipment upgrades and maintenance CAPEX rather than dropping straight to EBITDA.
• What to watch next quarter: The pace at which Agra, Panchkula, and the newly commissioned Rudrapur facility ramp toward their Year 1 EBITDA targets of 10–12%, and whether the CGHS revision meaningfully lifts realizations without being fully absorbed by reinvestment.

Growth Engine: Bed Expansion & Cluster Densification

• 960 beds added in 12 months: Bhatinda (250), Agra (360), and Panchkula (350) were all commissioned over the past year, pulling reported occupancy down mechanically while each ramps over several quarters.
• Rudrapur opens Q2: Acquired for ~₹177 crores all-cash, commissioned 2 August 2026 with all 330 beds functional; marks entry into the sixth state. Year 1 target: ₹100 cr revenue, ₹20–22 cr EBITDA.
• Zirakpur and Palam Vihar next: A 150-bed acquisition (₹107 cr) and a 100-bed Gurgaon extension will commission in November–December 2026, adding 250 beds not previously in the plan.
• Tricity cluster hits 1,000 beds: Panchkula (350), Mohali expansion to 350, and Zirakpur (150) create a dense northern hub positioned to capture patients from J&K and Himachal who would otherwise travel to Delhi.
• Pipeline fully funded to 5,740 beds by FY28: The entire identified expansion, 2,130 beds across FY27 and FY28 at a blended CAPEX of ₹36 lakhs per bed, is funded through internal accruals and IPO proceeds with no material fresh debt.

Dr. Ankit Gupta: "We will be at 5,740 beds capacity by FY'28, funded largely through internal accruals and IPO proceeds, without recourse to any fresh debts."

Unit Economics & Margin Resilience

• ARPOB rose 12% YoY to ₹30,444: Driven by a 440 bps shift in high-end super-specialty mix to ~62% of revenue, with mature hospitals like Gurgaon and Mohali growing at a steady 18–20%.
• ALOS improved 8% to 5.9 days: Operational efficiency gains shortened average length of stay from 6.4 days, supporting throughput even as new beds came online.
• New units carry lower Year 1 margins: Agra and Panchkula are expected to deliver 10–12% EBITDA in Year 1, not the 20–25% of mature units; management says mature hospitals will compensate to hold blended margins at 26–27% for FY27.
• Mohali as the proof case: Acquired with ₹52 lakhs revenue, now at ₹23 crores; Year 1 EBITDA of 12–13% grew to 18–19%, and FY27 is expected to touch 26%, demonstrating the ramp trajectory management expects from newer units.
• Debt nearly gone: Term debt (excluding lease liability) fell to ₹25.6 crores from ₹28.2 crores as of March 2026, removing interest burden and contributing to the 220 bps PAT margin expansion.

Rajesh Sharma: "So, we cannot see any challenge in terms of achieving the numbers. So, rather we are expecting that we will overachieve these numbers but just for a guidance purpose, we want to remain on these numbers."

Payer Mix & CGHS Rate Revision

• CGHS revision adds 7–7.5%: Partial impact began in Q1; fuller benefit expected from Q2, Q3 as revised rates flow through allied government agencies.
• Benefit reinvested, not dropped to EBITDA: Management explicitly stated the additional revenue will be utilized for high-end equipment, repair and maintenance CAPEX spending, so the revision supports asset quality rather than near-term margin expansion.
• Payer mix shifting toward private: Guided to move from the current 77:23 government-to-private split to 70:30 over the next 12–18 months, which would reduce debtor days toward a medium-term target of 125–130 days as government claim processing efficiency improves.
• Oncology insulated from CGHS risk: Contributing ~9–10% of revenue, with management having negotiated favorable rates with the vendor supply chain, so no adverse impact from the rate revision.

Dr. Sanjay Sharma: "But it will not directly translate into EBITDA because of this opportunity of rate revision we will also be utilising in upgrading our equipment and CAPEX spending with regard to the maintenance and better facilities in the hospitals."

Clinical Model & Doctor Retention

• Full-time, dedicated clinician model: All doctors are 100% employees with no visiting consultant policy; management attributes zero patient grievances to this structure, as clinicians focus solely on counseling and clinical outcomes.
• Attrition described as lowest in the industry: Retention levers include being one of the best paymasters, treating doctors as partners, accountability only for patient satisfaction and clinical outcomes (not revenue targets), monthly performance bonuses for clinicians scoring above 75%, and a robust ESOP system for clinicians and HoDs.
• Tier-2/3 recruitment working in Park's favor: Doctors from metros are returning to hometowns because Park brings high-end super-specialty facilities to those towns, removing the trade-off between practicing advanced medicine and living near family.
• Patient volume is brand-driven: Nearly 9 lakh footfall last FY and about 2.5 lakh in Q1 FY27; the Park brand generates its own patient volume so doctors do not need to worry about patient acquisition.
• OPD as a footfall generator, not a revenue center: Kept at low cost or free to avoid entry barriers; free OPDs run on gazetted holidays, with conversion happening when patients discover affordable treatment within their means.

Dr. Sanjay Sharma: "All our clinicians, doctors are full-time employees of Park Hospital and they are dedicated to Park only. We have no visiting consultant policy with us. All our doctors are 100%-dedicated and that is why there is zero patient grievances because their entire time goes in only two things -- one is the counselling of patient and attendants and other is on their skill sets coming out with high clinical outcomes."

Capital Allocation & Return Profile

• Return on capital at ~18%, rising: Management expects a 150–200 bps increase over the next 12–18 months as newer units mature and the blended asset base generates higher throughput.
• Promoter equity dilution on the horizon, no timeline: Minimum ~8% equity must be divested by December 2028; management said it is too early to comment on method or timing, and that clarity on deployment of funds would be the trigger.
• Rudrapur additional CAPEX capped: Not more than ₹10–12 crores expected beyond the ₹177 crores acquisition cost, keeping the all-in investment disciplined.
• No fresh debt in the plan: The entire growth roadmap to 5,740 beds by March 2028 is funded through internal accruals and IPO proceeds, with term debt excluding lease liability at ₹25.6 crores.

Sudesh Sharma: "We believe that densification gives a very, very durable competitive advantage in this business."

Guidance & Commitments

Key Metrics